FDA approves Guardant360 CDx assay as companion diagnostic for Menarini’s ORSERDU for metastatic breast cancer
Guardant Health, an oncology company, has secured the approval of the US Food and Drug Administration (FDA) for the company’s Guardant360 CDx liquid biopsy assay as a companion diagnostic for ORSERDU (elacestrant). The FDA approval as a companion diagnostic for ORSERDU marks Guardant Health’s first in breast cancer and the fifth for the Guardant360 CDx […]